

1017



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/720,006	12/19/2000	Johann Karl	RDID00115US	5872

23690 7590 06/15/2004

Roche Diagnostics Corporation
9115 Hague Road
PO Box 50457
Indianapolis, IN 46250-0457

EXAMINER

PADMANABHAN, KARTIC

ART UNIT	PAPER NUMBER
----------	--------------

1641

DATE MAILED: 06/15/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/720,006	Applicant(s) KARL ET AL.	
	Examiner Kartic Padmanabhan	Art Unit 1641	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 22 March 2004.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 44-52 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 44-52 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

2. Claims 44, 45, 49, and 51 are rejected under 35 U.S.C. 102(b) as being anticipated by Bellet et al. (US Pat. 5,011,771). The reference discloses an immunometric assay comprising the formation of a complex between antigen and multiple immobilized monoclonal antibodies against different epitopes of the antigen and with a detectably labeled monoclonal antibody (abstract). The sandwich or immunometric assay is meant to include simultaneous, forward, and reverse sandwich assays (Col. 5, lines 24-30). In a forward immunometric assay, sample is contacted with solid phase bound antibodies such that antigen in the sample is bound to the solid phase bound antibodies. Detectably labeled antibodies are then added to the solid phase. Labeled antibody on the solid phase is then detected as an indication of analyte presence (Cols. 5-6). The solid phase of the reference is an immunoabsorbent, which may be beads formed from glass, polystyrene, polypropylene, dextran, nylon, and other materials, or tubes formed or coated with such materials (Col. 8, lines 1-3). According to the reference, it is important that the multiple immobilized antibodies be bound in close proximity (Col. 8, lines 7-9). The monoclonal antibody may be labeled with any detectable label (Col. 8, lines 20-21). Any animal sample containing a detectable antigen can be used in the assay (Col. 8, lines 31-35). Any multivalent antigen can be detected with the assay of the reference, including viral antigens such

Art Unit: 1641

as Hepatitis B, Herpes Simplex viruses I and II, Herpes Virus Zoster, cytomegalovirus, Epstein-Barr virus, and Papova viruses such as measles, rubella, or influenza (Col. 8, lines 62-68). The materials for use in the assay are ideally suited for packaging in a kit (Col. 9, lines 62-63).

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

5. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

6. Claims 46-48, 50, and 52 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bellet et al. (US Pat. 5,011,771). The reference teaches a multiepitopic assay, as previously discussed under 35 USC 102(b). However, the reference does not teach the diameter of the test area, a control area, or latex particles as the label.

It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to use a control area and latex particles as the label with the method and kit of Bellet et al. One would have been motivated to do so because the use of a control area allows determination of background or baseline, which permits calibration of the assay system and a more sensitive measurement of analyte presence. In addition, since the reference teaches that any suitable label may be used, one could have used latex particles with a reasonable expectation of success. Further, the selection of a specific label simply represents an optimization of the assay protocol that one of skill in the art could have easily chosen based on preference. It has been held to be within the general skill of a worker in the art to select a known material on the basis of its suitability for the intended use as a matter of obvious design choice. *In re Leshin*, 125 USPQ 416. It would also have been obvious to use test areas with diameters less than 1 mm. The reference teaches that immobilized antibodies must be in close proximity to each other, and choosing the actual size of the area simply represents an optimization of the assay. It has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. *In re Aller*, 105 USPQ 233.

Response to Arguments

7. Applicant's arguments filed 3/22/04 have been fully considered and are persuasive to overcome the rejections based on Kuo, but they are not persuasive to overcome the rejections based upon Bellet.

8. Applicant argues that the examiner's interpretation of Bellet's disclosure of multiple immobilized antibodies in close proximity as qualifying as spatially separate test areas is in error, as the "skilled artisan would not make such an interpretation." Applicant goes on to lay out how a skilled artisan would interpret the Bellet reference (1 test area). However, this position is found unconvincing, as applicant has simply made a general conclusion as to how Bellet would be interpreted by one of skill in the art without providing any proof (in the form of declarations, affidavits, etc.). As such, a conclusion without any evidentiary basis is deemed *prima facie* unconvincing. Applicant alleges to have support for their position in the Bellet reference itself; however, it is unclear how the fact that antigen binds to the solid phase via both antibodies 1 and 2 as in Bellet provides support for applicant's position. Simply because antigen attaches to the solid phase via both immobilized antibodies, it does not necessarily follow that these antibodies must be in a single test area. Similarly, Bellet's teaching of the synergism of multiple different antibodies also does not provide support for applicant's position. Further, while Bellet may indeed teach that close proximity of the multiple immobilized antibodies is important, the claims to which the reference was applied under 35 USC 102(b) do not recite any requisite separation that would differentiate the claims over the reference. In the absence of a specific recitation of the requisite separation, spatial separation may properly be interpreted as even the most miniscule separation.

Art Unit: 1641

9. In response to applicant's argument that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., the distance between test areas) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

10. Applicant's arguments with respect to the rejection under 35 USC 103 are based upon the premise that the rejection under 35 USC 102 is not proper, a position which has already been addressed and found unpersuasive.

Conclusion

Claims 44-52 are rejected.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.


Art Unit: 1641

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kartic Padmanabhan whose telephone number is 571-272-0825. The examiner can normally be reached on M-F (8:30-5:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Kartic Padmanabhan
Patent Examiner
Art Unit 1641



LONG V. LE
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

06/10/04